Molecular insights into HR+/HER2+ early-stage breast cancer: Neoadjuvant therapy responses by MammaPrint and BluePrint genomic subtypes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results